C2i Genomics is a biotechnology company specializing in advanced genomic technologies for cancer detection and monitoring. The company focuses on providing innovative solutions that enhance precision medicine through the analysis of circulating tumor DNA (ctDNA). C2i Genomics aims to improve patient outcomes by enabling earlier diagnosis, treatment planning, and real-time monitoring of cancer progression and treatment response. Their platform leverages proprietary algorithms and comprehensive genomic data to deliver actionable insights for healthcare providers.